This paper explores the “Measures for the Management of Independent Directors of Listed Companies” announced on August 4, 2023, for Chinese listed firms. We find that firms failing to meet the criteria in the Measures suffer losses in the stock market. The 2023 Measures exogenously increase the demand for qualified independent directors and incur high search costs for firms facing more labor market constraints.
No takes yet. Share an insight, caveat, or question.
Jiao et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: